AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Adma Biologics Outperforms Market Amidst Revenue Growth Projections
ByAinvest
Wednesday, Jul 9, 2025 7:37 pm ET1min read
Adma Biologics (ADMA) stock ended at $18.34, up 2.98% from the previous day's close. The company is forecasted to report an EPS of $0.14 and revenue of $121.1 million in its upcoming release, marking a 7.69% and 12.98% increase from the same quarter last year. The Zacks Rank system has a proven track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. ADMA currently has a Zacks Rank of #4 (Sell) and a Forward P/E ratio of 29.2, which is premium compared to its industry's average.
Adma Biologics (ADMA) stock ended the recent trading session at $18.34, demonstrating a +2.98% change from the previous day's close. The stock outpaced the S&P 500's daily gain of 0.61% and the Dow's gain of 0.49%. The technology-centric Nasdaq increased by 0.95%. Coming into today, shares of the infectious disease drug developer had lost 14.62% in the past month. In that same time, the Medical sector lost 0.67%, while the S&P 500 gained 3.85%.Market participants will be closely following the financial results of Adma Biologics in its upcoming release. The company is forecasted to report an EPS of $0.14, showcasing a 7.69% upward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $121.1 million, indicating a 12.98% increase compared to the same quarter of the previous year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.61 per share and revenue of $505.8 million. These totals would mark changes of +24.49% and +18.61%, respectively, from last year.
The Zacks Rank system has a proven track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Adma Biologics currently has a Zacks Rank of #4 (Sell) and a Forward P/E ratio of 29.2, which is premium compared to its industry's average. The Medical - Biomedical and Genetics industry is part of the Medical sector and carries a Zacks Industry Rank of 75, placing it within the top 31% of over 250 industries.
References:
[1] https://www.marketbeat.com/instant-alerts/filing-adma-biologics-inc-nasdaqadma-shares-bought-by-principal-financial-group-inc-2025-07-09/
[2] https://www.nasdaq.com/articles/adma-biologics-adma-outperforms-broader-market-what-you-need-know
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet